INTRODUCTION
============

With the global increase in the proportion of the elderly population, clinical management catering to the elderly with diabetes has become increasingly important not only for pharmacologic management but also for diabetes self-management education (DSME). DSME is an established tool for improving clinical outcomes, such as for insulin use and self-care performance \[[@B1]\], metabolic outcome (glycemic control or lipid control) \[[@B2][@B3][@B4]\], rate of chronic complications \[[@B1]\], and degree of depressive symptoms \[[@B5]\].

While DSME is necessary and effective, it does not last long. Initial beneficial effects tend to diminish after approximately 6 months \[[@B2]\]. Therefore, physicians have recently focused on the use of continuing education as a new component of DSME. According to the recent recommendation by the American Diabetes Association, annual visits for diabetes education are recommended to assess all areas of self-management, even for those who meet the goals \[[@B6]\].

Among the many different types of DSME such as individual one-on-one education, group programs, and telemedicine, diabetes camp has proven to be an ideal environment for the continuing education of children and adolescents with type 1 diabetes mellitus (T1DM) and their families \[[@B7][@B8]\]. Although the concept of residential diabetes camps for children with T1DM has become widespread throughout the world, with over 46,000 campers in about 180 camps worldwide \[[@B9]\], there are only a limited number of reports of diabetes camps specialized for adults and/or elderly people with type 2 diabetes mellitus (T2DM). Moreover, the long-term metabolic benefits of diabetes camps in adult and/or elderly populations with T2DM have not been demonstrated, especially in terms of glycosylated hemoglobin (HbA1c) variability.

The aim of this study was to evaluate the effects of diabetes camps as a type of continuing DSME on long-term metabolic outcomes in middle-aged and elderly patients with T2DM.

METHODS
=======

Study subjects
--------------

We obtained clinical data and completed questionnaires from adult patients with T2DM who attended a diabetes camp held from August 21 to 24, 2012. The participants were recruited from the outpatient department of the Diabetes Center in Samsung Medical Center, Seoul, Republic of Korea. All participants except the patients\' family members were included in these analyses.

Clinical data (age, sex, body mass index \[BMI\], diabetes duration, diabetes treatment, underlying hypertension or dyslipidemia, history of smoking, and history of drug prescriptions) and laboratory measurements (HbA1c, fasting plasma glucose \[FPG\], postprandial 2-hour glucose \[PPG\], creatinine, cholesterol, high density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], and triglyceride \[TG\]) were obtained from electronic medical records. The depression quotient of each patient, psychological well-being score, and level of satisfaction with the camp were assessed using a questionnaire. The questionnaires were completed on the first and last days of the diabetes camp.

Case-control selection
----------------------

For each participant in the diabetes camp, up to two control patients were randomly selected by propensity score matching. The matching variables were age, sex, diabetes duration, and the levels of HbA1c before the education. The variables were categorized as age (≤40, 40 to 49, 50 to 59, 60 to 69, 70 to 79, 80 to 89, and ≥90), diabetes duration (\<1, 1 to 5, 5 to 10, and ≥10 years), and HbA1c (%; ≤6, 6 to 6.9, 7 to 7.9, 8 to 8.9, 9 to 9.9, and ≥10). Controls were selected from the clinical database of the 7,417 patients who received conventional DSME in the outpatient department from 2008 to 2016 in Samsung Medical Center, Seoul, Republic of Korea.

The protocol for this study was approved by the Institutional Review Board (IRB) of the Samsung Medical Center (IRB file No. 2012-08-004-001).

Organization of the diabetes camp
---------------------------------

Patients with T2DM aged 40 years and over were encouraged to attend the diabetes camp with registration on a first-come, first-served basis. Only individuals who were acutely ill or unable to attend the overnight camp were excluded. The cost per session was 380,000 Korean won (about \$325). The diabetes camp consisted of many planned activities including daily medical education lectures, small group discussions, and recreational activities provided by diabetes educators, registered dieticians, physicians, pharmacists, exercise educators, and social workers. Small groups were organized throughout the duration of the camp, encouraging emotional support within the group of participants. Blood glucose was tested for each camper six times a day and as needed. All participants kept individual records about their food choices, physical activity, and blood glucose levels, and received counseling if their blood glucose level was off-target. The participants kept a diabetes diary and wrote a daily list of goals or promises about diabetes self-management before bed. For patients using insulin, insulin was adjusted before each meal by the staff. All insulin injections were supervised, and all meals were planned by the registered dietitian. There were two attending physicians to supervise the participants and for medical decisions in case of a medical emergency.

Outcome measures
----------------

To compare the short-term effects of the diabetic camp, we obtained laboratory parameters (HbA1c, FPG, PPG, and lipid profiles) measured at the closest outpatient clinic before and after the camp, respectively.

To compare the long-term effects of the diabetes camp on glycemic control, we analyzed the variability of HbA1c levels. The measurements of HbA1c were performed every 3 months for 15 months (maximum five times) before the camp and after the camp, respectively. HbA1c was measured an average of 3.61 times during the 15-month period before the camp and 3.35 times during the 15-month period after the camp. Three patients who failed to check their HbA1c levels at least two times before and two times after the camp (for a total of at least four times) were excluded from the analysis of HbA1c variability. Since some patients had already achieved very strict glycemic control before the camp, a subgroup analysis was conducted for those whose mean HbA1c measured during the 15 months before the camp was ≥6.5% (*n*=40) and those whose HbA1c was \<6.5% (*n*=14). In addition, a subgroup analysis was conducted for those whose duration of diabetes was ≥15 and \<15 years. The interpersonal mean, standard deviation (SD), and coefficient of variance (CV) of HbA1c were calculated. The CV was calculated by dividing the SD by the mean. We also calculated the adjusted SD of HbA1c by dividing with \[*n*/(*n*--1)\]^0.5^ (where *n* is the number of HbA1c measurements) to adjust for the effect of varying numbers of HbA1c measurements.

To analyze the effect of medication on the metabolic outcomes, we analyzed the serial changes in the number of diabetes medications before and after the camp. Drug compliance was described as the medication possession ratio (MPR), which is calculated as the sum of the number of days that medication was taken during the observational period divided by the number of days elapsed during the period. We defined medication adherence as an MPR ≥80%.

To evaluate the psychosocial outcomes, questionnaire data were collected from the participants before and after the camp. Three of the participants who did not complete the questionnaires after the camp were excluded from these analyses. The depression quotient was assessed using the Center for Epidemiologic Studies Depression (CES-D) scale. The CES-D scale is a reliable instrument for screening for depression in patients with different disorders, including diabetes, which is sensitive to changes in care-receiver depressive symptoms after intervention \[[@B10][@B11]\]. The score ranges from 0 to 60, with high scores indicating greater depressive symptoms. Psychological well-being was assessed using the World Health Organization 5-item (WHO-5) Well-Being Index. The total score ranged from 0 (absence of well-being) to 25 (maximal well-being). The WHO-5 index has been validated in different samples, including patients with diabetes \[[@B12][@B13]\].

Statistical analysis
--------------------

We calculated the numerical data using mean±SD or median (range), while the categorical data were calculated using counts and percentages. The Wilcoxon signed-rank test was used to compare glycometabolic parameters. The CES-D scale and WHO-5 index were also compared using the Wilcoxon signed-rank test and McNemar\'s test.

Analysis of covariance (ANCOVA) was used to compare metabolic outcomes in two groups: the group that attended the diabetes camp and a matched control group that received conventional education in an outpatient clinic. The dependent variable was each parameter of metabolic outcomes after the diabetes camp or conventional DSME. The covariate was each parameter of metabolic outcomes before the diabetes camp or conventional DSME. The fixed factor was the group difference.

A linear mixed model was used to analyze repeatedly measured HbA1c to compare the effect of the diabetes camp with that of the conventional education. A comparison of differences between the groups over time was performed using a group by time interaction.

Statistical analysis was executed using IBM SPSS Statistics 23.0 (IBM Co., Armonk, NY, USA) and SAS version 9.4 (SAS Institute, Cary, NC, USA). A *P* value of \<0.05 was considered significant.

RESULTS
=======

Baseline characteristics of the study subjects
----------------------------------------------

A total of 57 patients participated in the diabetes camp. The median age was 65 years (range, 50 to 86). After propensity score matching, 93 control patients were selected from the source cohort. The baseline characteristics of the participants in the diabetic camp and matched controls are summarized in [Table 1](#T1){ref-type="table"}. Among the 57 participants of the diabetes camp, three had no matched controls and therefore were excluded from the subsequent case-control analysis. Despite the propensity score matching, there were several differences in baseline characteristics between the groups, including greater BMI, greater proportion of patients on lifestyle modification alone, and higher FPG and LDL-C levels in the matched controls ([Table 1](#T1){ref-type="table"}).

Changes in the metabolic outcomes after the diabetes camp and conventional education
------------------------------------------------------------------------------------

In participants of the diabetes camp, the levels of HbA1c and LDL-C were significantly lower after the diabetes camp than before the diabetes camp (*P*=0.022 and *P*=0.011). There were no significant differences in the levels of FPG, PPG, cholesterol, TG, HDL-C, and BMI before and after the diabetes camp ([Table 2](#T2){ref-type="table"}).

In the matched control group, BMI and the levels of FPG and HbA1c were significantly lower after the conventional education than before the education (*P*=0.021, *P*=0.002, and P=0.005, respectively) ([Table 2](#T2){ref-type="table"}).

When the changes from baseline in metabolic outcomes among the participants of the diabetes camp were compared to those of the matched controls by ANCOVA, the decrease from baseline in LDL-C levels in the participants of the diabetes camp was significantly greater than those of the matched controls (*P*=0.036). In this analysis, the decrease in BMI from baseline in the matched controls was greater than those of the participants of the diabetes camp (*P*=0.031). Changes in the FPG, PPG, HbA1c, cholesterol, TG, and HDL-C levels were not significantly different in this analysis ([Table 2](#T2){ref-type="table"}).

The levels of HbA1c (*P*=0.341) ([Supplementary Fig. 1](#S4){ref-type="supplementary-material"}) and BMI (*P*=0.084) ([Supplementary Fig. 2](#S5){ref-type="supplementary-material"}) during the first year after each education was not different between the groups overall.

Psychosocial outcomes
---------------------

The WHO-5 well-being index increased after the camp experience and was significantly different from the values before the camp (*P*\<0.0001). The CES-D score, an indicator of depression symptoms, was lower after the camp and was also significantly different from the values before the camp (*P*=0.0035) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). On the basis of WHO-5 and CES-D scores, there were seven (three identical and four non-identical) patients with scores suggestive of depression at baseline. The proportion of the participants with a WHO-5 score of ≤12 (*P*=0.031) but not a CES-D score of \<16 (*P*=0.158) decreased significantly after the diabetes camp. Among these patients, one patient took a selective serotonin uptake inhibitor and there was no change in the dose after the diabetes camp.

Changes in medication prescriptions after the diabetes camp and conventional education
--------------------------------------------------------------------------------------

The number of glucose-lowering medications at 6 months did not change in 49 of 55 (88%) diabetes camp participants and in 57 of 89 (65%) control patients (*P*=0.001). The details of the changes in prescriptions after the diabetes camp and conventional education are summarized in [Supplementary Table 2](#S2){ref-type="supplementary-material"}. The MPR and medication adherence (defined as an MPR ≥80%) before and after the diabetes camp were not significantly different (76.33±21.33 vs. 76.41±21.97, *P*=0.757; 24 \[42.1%\] vs. 25 \[43.9%\], *P*=1.000). The MPR and adherence rate before the conventional education were not available for the majority of the control patients.

Among the 57 patients who attended the diabetes camp, 33 patients (57%) were taking lipid-lowering agents before the camp and three patients (5.3%) received new prescriptions for lipid-lowering agents after the camp. Among the 93 control patients, 43 patients (46%) were taking lipid-lowering agents before the education and 18 patients (19%) received new prescriptions for lipid-lowering agents after the education.

One-year mean and variability of glycemic parameters before and after the diabetes camp
---------------------------------------------------------------------------------------

Besides the case-control analysis, the 1-year variability of HbA1c, FPG, and PPG after the diabetes camp in its participants was compared with their own 1-year variability of HbA1c, FPG, and PPG before the diabetes camp. In all participants of the diabetes camp, the 1-year mean and SD of HbA1c improved (*P*=0.010 and *P*=0.041). The adjusted SD and CV of HbA1c were not significantly different in this analysis.

After the exclusion of subjects with a mean HbA1c of \<6.5% before the camp, the mean, SD, adjusted SD, and CV of HbA1c significantly improved ([Table 3](#T3){ref-type="table"}). The 1-year mean and variability of FPG was not significantly different in all subjects and in patients whose HbA1c was ≥6.5% before the camp. However, the SD and CV of PPG were significantly improved after the diabetes camp ([Table 3](#T3){ref-type="table"}). The 1-year mean, SD, adjusted SD, and CV of HbA1c significantly improved after the diabetes camp in the subjects with diabetes duration of \<15 years ([Supplementary Table 3](#S3){ref-type="supplementary-material"}).

Serial changes in HbA1c during the 15 months before and 15 months after the diabetes camp are shown in [Fig. 1](#F1){ref-type="fig"}. In the control group, the 1-year mean for HbA1c before the conventional DSME was not available for the majority of the subjects.

DISCUSSION
==========

In this study, the metabolic benefits of the diabetes camp as a continuing DSME for middle-aged adults and the elderly with T2DM were comparable to those of conventional DSME, even though fewer changes in medications occurred with the group who attended the camp than with those who received conventional DSME. In the participants of the diabetes camp, long-term benefits to glycemic control were observed in terms of the 1-year mean and SD of HbA1c. The 1-year adjusted SD and CV of HbA1c were improved in those with a baseline mean HbA1c of ≥6.5% and a diabetes duration of \<15 years.

The typical subjects in this study were older, had diabetes for a long time, and used oral antidiabetes medications. Because the effect of a diabetes camp has almost been exclusively examined in children and adolescents with T1DM, little is known about the benefits of a diabetes camp in the elderly population \[[@B14]\]. In contrast to the conventional DSME typically offered at the time of initial diabetes diagnosis, the effect of diabetes camp as a continuing diabetes education in patients with a long duration of diabetes has not been extensively investigated. In this study, the improvements in both metabolic outcomes and depression indices were consistent with those reported in the diabetes camp for children/adolescents with T1DM \[[@B7][@B8][@B15][@B16]\]. Compared to the matched controls that received conventional DSME, the participants of the diabetes camp showed more reductions in LDL-C levels in 3 to 6 months after the diabetes camp and comparable glycometabolic parameters during the 1 year after the education despite fewer changes in lipid-lowering and glucose-lowering drug regimens. However, these results should be interpreted in the context of different baseline characteristics between the two groups despite the propensity for score-matching. When compared to their own 1-year variability in HbA1c, FPG, and PPG before the diabetes camp, the 1-year adjusted SD and CV of HbA1c were significantly reduced after the diabetes camp in participants with a baseline mean HbA1c of ≥6.5% and a diabetes duration of \<15 years. These results indicate that diabetes camp as a continuing renewal education can also be effective in middle-aged and elderly patients, although more attention has been focused on conventional DSME for patients with new-onset diabetes.

Several factors in this study can explain the positive effects of diabetes camp. First, the sustained positive impacts of the diabetes camp were demonstrable in terms of the 1-year variability of HbA1c and PPG rather than the 1-year variability of FPG, with fewer changes in the prescription of glucose-lowering medications than in matched controls. In contrast, the majority of the matched controls received the conventional DSME when they followed up at the outpatient clinic for less than several months, and the medications were changed in a higher proportion of these patients than in the participants of the diabetes camp. Although the data are not sufficient to fully explain the difference, we speculate that more consistent adherence to the instructions for reducing PPG such as avoidance of foods with high glycemic index and increasing post-meal physical activity could be one of the contributing factors to the positive outcomes. Second, the emotional support provided by fellow camp participants and the caregivers was effective in improving the emotional status of the participants, as reflected in the WHO-5 well-being index and the CES-D scores obtained immediately after the diabetes camp. Each of these indices also improved in six out of seven participants whose score before the camp was in a range suggesting depression. Although the long-term effects of the diabetes camp on these indices were not identified, the results could indicate that improvement in emotional status could be a contributor to the improved metabolic outcomes in elderly people with T2DM \[[@B17][@B18][@B19]\]. This should be confirmed in future studies with longer follow-up periods.

One of the strengths of this study lies in the documentation of HbA1c variability, rather than tabulation of only the absolute levels of HbA1c at each point. HbA1c variability has been increasingly reported as an independent risk factor for chronic complications of diabetes \[[@B20][@B21][@B22]\]. HbA1c at the baseline itself does not provide information on the baseline status of the glycemic control over 1 year because it cannot discriminate a subject with a temporarily low or high HbA1c only at baseline regardless of the actual glycemic control over 1 year. Analysis of the 1-year mean and variability of HbA1c can better represent the longer-term glycemic control. To our knowledge, this is the first report to demonstrate that diabetes camp can reduce HbA1c variability as well as HbA1c values. Notably, the reduced 1-year adjusted SD and CV of HbA1c was observed only in the participants of diabetes camp with a baseline mean HbA1c of ≥6.5% and a diabetes duration of \<15 years. These results might reflect the difficulty in making an impact by continuing renewal education in participants already with very strict glucose control or very long duration of diabetes.

Several limitations of the study should be discussed. First, because of the retrospective case-control study design, the data were insufficient to explain the reason for the positive impact of the diabetes camp. For example, depression scores were obtained only immediately after the diabetes camp, and a detailed description of the diet and exercise before and after the diabetes camp was not possible. Second, a 1-year variability of glycemic parameters before the conventional DSME was not available for the majority of the patients in the matched control group because they did not visit the outpatient clinic ≥2 times before the conventional DSME. Although we screened more than 7,000 patients who received DSME in our outpatient clinic, in most cases, DSME was routinely prescribed within the first few visits to our clinic.

In conclusion, diabetes camp as a continuing DSME in middle-aged adults and elderly people with T2DM showed metabolic outcomes comparable to those of the conventional DSME despite fewer increases in drug regimens. Moreover, in participants of the diabetes camp with a baseline 1-year mean HbA1c of ≥6.5% and a diabetes duration of \<15 years, sustained benefits of glycemic control were demonstrated in terms of a 1-year adjusted SD and CV of HbA1c. The results of this study support the use of the diabetes camp as an effective tool for continuing DSME in this population.
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###### Supplementary Table 1

Comparison of psychosocial outcomes before and after the diabetes camp (*n*=54^a^)

###### Supplementary Table 2

Changes in the number of glucose-lowering medications at 6 months after the diabetes camp or conventional education^a^

###### Supplementary Table 3

Comparison of the 1-year mean variability in glycosylated hemoglobin before and after the diabetes camp in participants with diabetes duration of \<15 years (*n*=32^a^)

###### Supplementary Fig. 1

Serial changes in glycosylated hemoglobin (HbA1c) from before the diabetes camp to 15 months after the diabetes camp or conventional diabetes self-management education. The error bars represent standard deviations of HbA1c; *n* is the number of patients who checked their HbA1c levels at each time point.

###### Supplementary Fig. 2

Serial changes in body mass index (BMI) from before the diabetes camp to 15 months after the diabetes camp or conventional diabetes self-management education.

![Serial changes in glycosylated hemoglobin (HbA1c) before and after the diabetes camp. The error bars represent the standard deviation of HbA1c; *n* is the number of patients who checked their HbA1c levels at each time point.](dmj-41-99-g001){#F1}

###### Baseline characteristics of participants in the diabetes camp and matched controls

![](dmj-41-99-i001)

  Characteristic                              All participants in diabetes camp (*n*=57)   Matched controls (*n*=93^a^)   *P* value^b^
  ------------------------------------------- -------------------------------------------- ------------------------------ --------------
  Age, yr                                     65 (50--86)                                  62 (51--87)                    0.285
  Male sex                                    27 (47.4)                                    45 (48.4)                      0.904
  BMI, kg/m^2^                                23.45±2.75                                   24.49±2.92                     0.048
  Diabetes duration, yr                       14 (1--48)                                   11 (1--51)                     0.086
  Hypertension                                28 (49.1)                                    47 (50.54)                     0.866
  Dyslipidemia                                31 (54.4)                                    43 (46.24)                     0.333
  Diabetes treatment                                                                                                      0.003
   Lifestyle modification only                7 (12.3)                                     35 (37.63)                     
   Oral diabetes medication                   44 (77.2)                                    49 (52.69)                     
   Oral diabetes medication plus insulin^c^   6 (10.5)                                     9 (9.68)                       
  HbA1c, %                                    7.08±0.97                                    7.18±0.92                      0.394
  FPG, mg/dL                                  127.96±23.40                                 149.29±49.54                   0.015
  PPG, mg/dL                                  199.60±59.47                                 211.14±70.10                   0.233
  Creatinine, mg/dL                           0.87±0.21                                    1.15±0.88                      0.060
  Cholesterol, mg/dL                          157.40±32.07                                 174.01±36.25                   0.007
  TG, mg/dL                                   102.47±50.38                                 118.20±58.02                   0.065
  HDL-C, mg/dL                                55.21±16.46                                  55.84±16.46                    0.739
  LDL-C, mg/dL                                90.07±28.57                                  103.68±32.03                   0.015

Values are presented as median (range), number (%), or mean±standard deviation.

BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PPG, postprandial 2-hour glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

^a^Three participants of diabetes camp were not matched because the matched controls were not available. One was a 76-year-old male with 28 years of diabetes duration and 8.1% of HbA1c, another was a 61-year-old female with 13 years of diabetes duration and 9.0% of HbA1c, and the other was a 62-year-old female with 13 years of diabetes duration and 6.4% of HbA1c, ^b^Comparisons were performed using the Mann-Whitney test or the chi-square test, ^c^Basal insulin once daily (*n*=5); multiple daily insulin injection (*n*=1).

###### The comparison of metabolic outcomes before and 3 to 6 months after the diabetes camp or conventional education

![](dmj-41-99-i002)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter            Participants of the diabetes camp (*n*=57)   Matched controls (*n*=93)   *P* value^b^\                                              
                                                                                                (case vs. control)                                         
  -------------------- -------------------------------------------- --------------------------- -------------------- -------------- -------------- ------- -------
  BMI, kg/m^2^         23.45±2.75                                   23.71±2.74                  0.431                24.49±2.92     24.22±2.90     0.021   0.036

  HbA1c, %             7.08±0.97                                    6.90±0.87                   0.022                7.18±0.92      6.96±1.05      0.005   0.915

  FPG, mg/dL           127.96±23.48                                 124.58±20.15                0.330                149.29±49.54   137.36±39.03   0.002   0.344

  PPG, mg/dL           199.60±59.47                                 189.24±63.23                0.428                211.14±70.10   197.76±75.81   0.104   0.515

  Cholesterol, mg/dL   157.40±32.07                                 152.29±26.93                0.524                1.15±0.88      164.95±35.74   0.055   0.427

  TG, mg/dL            102.47±50.38                                 94.86±56.02                 0.280                174.01±36.25   117.53±58.82   0.175   0.575

  HDL-C, mg/dL         55.21±16.46                                  58.69±19.38                 0.061                55.84±16.46    56.78±15.41    0.071   0.360

  LDL-C, mg/dL         90.07±28.57                                  82.02±25.18                 0.011                103.68±32.03   97.85±29.02    0.222   0.031
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as mean±standard deviation.

BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PPG, postprandial 2-hour glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

^a^Comparisons were performed using the Wilcoxon signed-rank test, ^b^Among the 57 participants of the diabetes camp, three who had no matched controls were excluded from this case-control analysis. Comparisons were performed using analysis of covariance.

###### The comparison of the 1-year mean variability of glycosylated hemoglobin before and after the diabetes camp

![](dmj-41-99-i003)

  Parameter                                                        3--15 Months before the camp   3--15 Months after the camp   *P* value^a^
  ---------------------------------------------------------------- ------------------------------ ----------------------------- --------------
  In all patients (*n*=57)                                                                                                      
   Mean and variability of HbA1c (*n*=54^b^)                                                                                    
    Mean of HbA1c, %                                               7.11±0.98                      6.95±0.87                     0.010
    SD of HbA1c, %                                                 0.34±0.32                      0.27±0.21                     0.041
    Adjusted SD of HbA1c, %                                        0.11±0.08                      0.09±0.06                     0.103
    CV of HbA1c                                                    0.05±0.04                      0.04±0.03                     0.065
   Mean and variability of FPG (*n*=50^b^)                                                                                      
    Mean of FPG, mg/dL                                             129.96±22.34                   127.88±20.46                  0.705
    SD of FPG, mg/dL                                               16.28±14.90                    16.91±16.73                   0.554
    Adjusted SD of FPG, mg/dL                                      5.71±5.01                      6.58±8.46                     0.901
    CV of FPG                                                      0.12±0.09                      0.13±0.15                     0.678
   Mean and variability of PPG (*n*=45^b^)                                                                                      
    Mean of PPG, mg/dL                                             200.95±49.08                   193.20±58.43                  0.136
    SD of PPG, mg/dL                                               38.36±21.80                    31.05±17.63                   0.108
    Adjusted SD of PPG, mg/dL                                      14.29±11.90                    13.27±9.27                    0.835
    CV of PPG                                                      0.19±0.11                      0.17±0.10                     0.225
  In the patients whose HbA1c was ≥6.5% before the camp (*n*=43)                                                                
   Mean and variability of HbA1c (*n*=40^b^)                                                                                    
    Mean of HbA1c, %                                               7.45±0.89                      7.23±0.83                     0.003
    SD of HbA1c, %                                                 0.41±0.34                      0.31±0.22                     0.026
    Adjusted SD of HbA1c, %                                        0.13±0.09                      0.10±0.07                     0.049
    CV of HbA1c                                                    0.05±0.04                      0.04±0.03                     0.045
   Mean and variability of FPG (*n*=37^b^)                                                                                      
    Mean of FPG, mg/dL                                             135.56±25.57                   131.44±21.40                  0.300
    SD of FPG, mg/dL                                               19.12±16.11                    20.24±18.15                   0.789
    Adjusted SD of FPG, mg/dL                                      6.59±5.36                      7.54±9.49                     0.649
    CV of FPG                                                      0.14±0.10                      0.16±0.17                     0.946
   Mean and variability of PPG (*n*=34^b^)                                                                                      
    Mean of PPG, mg/dL                                             217.60±43.09                   209.31±56.80                  0.135
    SD of PPG, mg/dL                                               41.41±22.05                    29.30±14.95                   0.013
    Adjusted SD of PPG, mg/dL                                      15.56±12.99                    11.90±6.56                    0.285
    CV of PPG                                                      0.20±0.11                      0.14±0.07                     0.018

Values are presented as mean±standard deviation.

HbA1c, glycosylated hemoglobin; SD, standard deviation; CV, coefficient of variation; FPG, fasting plasma glucose; PPG, postprandial 2-hour glucose.

^a^Comparisons were performed using the Wilcoxon signed-rank test, ^b^Of the total of 57 patients, those who failed to check the outcomes at least two times in the 15 months before and two times in the 15 months after the camp were excluded.
